Mark Andrew Wilson Nektar Therapeutics (NKTR) insider trading activity

NKTR Quotes by TradingView

Mark Andrew Wilson is Chief Legal Officer of NEKTAR THERAPEUTICS. Currently has a direct ownership of 385,294 shares of NKTR, which is worth approximately $358,323. The most recent transaction as insider was on Dec 13, 2024, when has been sold 165,938 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 385K
71.04% 3M change
58.05% 12M change
Total Value Held $358,323

Mark Andrew Wilson Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 13 2024
BUY
Grant, award, or other acquisition
-
165,938 Added 30.1%
385,294 Common Stock
Nov 19 2024
SELL
Open market or private sale
$6,471 $1.01 p/Share
6,407 Reduced 2.84%
218,856 Common Stock
Aug 19 2024
SELL
Open market or private sale
$7,233 $1.28 p/Share
5,651 Reduced 2.45%
225,263 Common Stock
May 17 2024
SELL
Open market or private sale
$10,955 $1.75 p/Share
6,260 Reduced 2.64%
230,414 Common Stock
Feb 20 2024
SELL
Open market or private sale
$5,172 $0.68 p/Share
7,606 Reduced 3.11%
236,674 Common Stock
Nov 17 2023
SELL
Open market or private sale
$3,517 $0.49 p/Share
7,179 Reduced 2.86%
243,780 Common Stock
Aug 16 2023
SELL
Open market or private sale
$5,632 $0.78 p/Share
7,221 Reduced 2.8%
250,959 Common Stock
May 16 2023
SELL
Open market or private sale
$5,430 $0.72 p/Share
7,543 Reduced 2.84%
257,680 Common Stock
Feb 16 2023
SELL
Open market or private sale
$24,825 $3.0 p/Share
8,275 Reduced 3.03%
265,223 Common Stock
Nov 16 2022
SELL
Open market or private sale
$31,023 $3.57 p/Share
8,690 Reduced 3.09%
272,498 Common Stock
Aug 16 2022
SELL
Open market or private sale
$15,180 $4.76 p/Share
3,189 Reduced 1.12%
281,188 Common Stock
Aug 15 2022
BUY
Grant, award, or other acquisition
-
165,938 Added 36.85%
284,377 Common Stock
May 16 2022
SELL
Open market or private sale
$12,387 $3.95 p/Share
3,136 Reduced 2.59%
117,939 Common Stock
Feb 16 2022
SELL
Open market or private sale
$40,088 $10.95 p/Share
3,661 Reduced 2.93%
121,075 Common Stock
Dec 16 2021
BUY
Grant, award, or other acquisition
-
37,800 Added 23.26%
124,736 Common Stock
Nov 16 2021
SELL
Open market or private sale
$86,382 $13.16 p/Share
6,564 Reduced 7.06%
86,436 Common Stock
Nov 15 2021
BUY
Grant, award, or other acquisition
-
20,100 Added 17.77%
93,000 Common Stock
Aug 16 2021
SELL
Open market or private sale
$26,415 $13.83 p/Share
1,910 Reduced 2.55%
72,900 Common Stock
May 17 2021
SELL
Open market or private sale
$35,081 $18.3 p/Share
1,917 Reduced 2.5%
74,810 Common Stock
Feb 16 2021
SELL
Open market or private sale
$48,610 $22.37 p/Share
2,173 Reduced 2.75%
76,727 Common Stock
Feb 03 2021
SELL
Open market or private sale
$103,941 $19.45 p/Share
5,344 Reduced 6.34%
78,900 Common Stock
Feb 03 2021
SELL
Exercise of conversion of derivative security
$47,027 $8.8 p/Share
5,344 Reduced 5.97%
84,244 Common Stock
Dec 18 2020
BUY
Grant, award, or other acquisition
-
28,550 Added 26.57%
78,900 Common Stock
Nov 16 2020
SELL
Open market or private sale
$26,055 $16.93 p/Share
1,539 Reduced 2.99%
49,850 Common Stock
MAW

Mark Andrew Wilson

Chief Legal Officer
San Francisco, CA

Track Institutional and Insider Activities on NKTR

Follow NEKTAR THERAPEUTICS and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NKTR shares.

Notify only if

Insider Trading

Get notified when an Nektar Therapeutics insider buys or sells NKTR shares.

Notify only if

News

Receive news related to NEKTAR THERAPEUTICS

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on NKTR